...
search icon
verv-img

Verve Therapeutics Inc, Common Stock

VERV

NSQ

$4.29

-$0.07

(-1.61%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$389.56M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.83M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.83
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.86 L
$9.3 H
$4.29

About Verve Therapeutics Inc, Common Stock

Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company's product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVERVSectorS&P500
1-Week Return-6.94%-3.24%-2.29%
1-Month Return-25.13%-5.96%5.13%
3-Month Return-30.81%-11.47%-1.04%
6-Month Return-25.78%-11.3%-3.3%
1-Year Return-18.13%-8.64%9.3%
3-Year Return-72.59%-2.75%39.44%
5-Year Return-86.56%29.73%90.79%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue--1.94M11.76M32.33M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":6,"profit":true},{"date":"2023-12-31","value":36.37,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue1.33M3.38M6.71M5.46M6.75M[{"date":"2020-12-31","value":19.67,"profit":true},{"date":"2021-12-31","value":50.01,"profit":true},{"date":"2022-12-31","value":99.38,"profit":true},{"date":"2023-12-31","value":80.78,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(1.33M)(3.38M)(4.77M)6.30M25.58M[{"date":"2020-12-31","value":-5.19,"profit":false},{"date":"2021-12-31","value":-13.2,"profit":false},{"date":"2022-12-31","value":-18.65,"profit":false},{"date":"2023-12-31","value":24.64,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin--(245.75%)53.61%79.11%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-310.63,"profit":false},{"date":"2023-12-31","value":67.76,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses40.63M87.07M167.63M234.88M260.99M[{"date":"2020-12-31","value":15.57,"profit":true},{"date":"2021-12-31","value":33.36,"profit":true},{"date":"2022-12-31","value":64.23,"profit":true},{"date":"2023-12-31","value":90,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(40.63M)(87.07M)(165.69M)(223.12M)(228.66M)[{"date":"2020-12-31","value":-4062700000,"profit":false},{"date":"2021-12-31","value":-8706700000,"profit":false},{"date":"2022-12-31","value":-16568700000,"profit":false},{"date":"2023-12-31","value":-22312400000,"profit":false},{"date":"2024-12-31","value":-22866000000,"profit":false}]
Total Non-Operating Income/Expense(4.92M)(33.10M)15.22M44.66M59.06M[{"date":"2020-12-31","value":-8.32,"profit":false},{"date":"2021-12-31","value":-56.05,"profit":false},{"date":"2022-12-31","value":25.77,"profit":true},{"date":"2023-12-31","value":75.61,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(45.70M)(120.31M)(157.33M)(199.79M)(198.36M)[{"date":"2020-12-31","value":-4570400000,"profit":false},{"date":"2021-12-31","value":-12031400000,"profit":false},{"date":"2022-12-31","value":-15733400000,"profit":false},{"date":"2023-12-31","value":-19979300000,"profit":false},{"date":"2024-12-31","value":-19836000000,"profit":false}]
Income Taxes(162.00K)(1.68M)53.00K275.00K349.00K[{"date":"2020-12-31","value":-46.42,"profit":false},{"date":"2021-12-31","value":-480.52,"profit":false},{"date":"2022-12-31","value":15.19,"profit":true},{"date":"2023-12-31","value":78.8,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(45.54M)(118.64M)(157.39M)(200.07M)(198.71M)[{"date":"2020-12-31","value":-4554200000,"profit":false},{"date":"2021-12-31","value":-11863700000,"profit":false},{"date":"2022-12-31","value":-15738700000,"profit":false},{"date":"2023-12-31","value":-20006800000,"profit":false},{"date":"2024-12-31","value":-19870900000,"profit":false}]
Income From Continuous Operations(45.70M)(120.31M)(157.39M)(192.80M)(198.71M)[{"date":"2020-12-31","value":-4570400000,"profit":false},{"date":"2021-12-31","value":-12031400000,"profit":false},{"date":"2022-12-31","value":-15738700000,"profit":false},{"date":"2023-12-31","value":-19280100000,"profit":false},{"date":"2024-12-31","value":-19870900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(45.54M)(118.64M)(157.39M)(200.07M)(198.71M)[{"date":"2020-12-31","value":-4554200000,"profit":false},{"date":"2021-12-31","value":-11863700000,"profit":false},{"date":"2022-12-31","value":-15738700000,"profit":false},{"date":"2023-12-31","value":-20006800000,"profit":false},{"date":"2024-12-31","value":-19870900000,"profit":false}]
EPS (Diluted)(4.99)(8.40)(2.92)(3.12)(2.35)[{"date":"2020-12-31","value":-499.31,"profit":false},{"date":"2021-12-31","value":-840,"profit":false},{"date":"2022-12-31","value":-292,"profit":false},{"date":"2023-12-31","value":-312,"profit":false},{"date":"2024-12-31","value":-235,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VERV
Cash Ratio 9.56
Current Ratio 9.84

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VERV
ROA (LTM) -19.35%
ROE (LTM) -34.26%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VERV
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VERV
Trailing PE NM
Forward PE NM
P/S (TTM) 6.52
P/B 0.82
Price/FCF NM
EV/R 1.97
EV/Ebitda NM

FAQs

What is Verve Therapeutics Inc share price today?

Verve Therapeutics Inc (VERV) share price today is $4.29

Can Indians buy Verve Therapeutics Inc shares?

Yes, Indians can buy shares of Verve Therapeutics Inc (VERV) on Vested. To buy Verve Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VERV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Verve Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Verve Therapeutics Inc (VERV) via the Vested app. You can start investing in Verve Therapeutics Inc (VERV) with a minimum investment of $1.

How to invest in Verve Therapeutics Inc shares from India?

You can invest in shares of Verve Therapeutics Inc (VERV) via Vested in three simple steps:

  • Click on Sign Up or Invest in VERV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Verve Therapeutics Inc shares
What is Verve Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Verve Therapeutics Inc (VERV) is $9.3. The 52-week low price of Verve Therapeutics Inc (VERV) is $2.86.

What is Verve Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Verve Therapeutics Inc (VERV) is 0.82

What is the Market Cap of Verve Therapeutics Inc?

The market capitalization of Verve Therapeutics Inc (VERV) is $389.56M

What is Verve Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Verve Therapeutics Inc is VERV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top